CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
(World News Science)

Media Update CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older Positive opinion based on clinical data demonstrating safety and efficacy of Supemtek® for adults aged 18 and older demonstrated in two Phase 3 randomized controlled trials involving more than 10,000 patients The European Commission (EC) final decision is expected in Q4 2020 Sanofi and GSK`s COVID-19 vaccine candidate is based on the same technology platform MEDIA UPDATE POSTED ON SEPTEMBER 22, 2020 The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Supemtek®...